Bone marrow transplantation without myeloablation for sickle cell disease

New England Journal of Medicine

Volumn 344, Issue 1, 2001, Pages 68-

  Krishnamurti, L ^a   Blazar, B R ^a   Wagner, J E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DEFEROXAMINE; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CASE REPORT; CHELATION THERAPY; CLINICAL FEATURE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; THROMBOCYTE TRANSFUSION;

ANEMIA, SICKLE CELL; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; HUMANS; TRANSPLANTATION CONDITIONING;

EID: 0035804287     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200101043440119     Document Type: Letter

References (5)

1. Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report
2. Bone marrow transplantation for hemoglobinopathies
3. Reinventing bone marrow transplantation: Reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy
4. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies
5. Nonmyeloablative stem cell transplants